Weekly Recap: Jideytro FDA filing for ROS1—positive NSCLC and £2bn R&D cost cuts
GSK plc Sponsored ADR (LSE:GSK) is pressing its oncology and vaccine advantages—pursuing FDA expansion for Jideytro after strong ROS1—positive NSCLC results and growing SHINGRIX uptake—while reallocating about £2bn to R&D, trimming specialty portfolios and closing its Dresden flu plant to shift pro…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.